Table 3  Dermatologist’s diagnosis.

<table>
<thead>
<tr>
<th>Skin disease</th>
<th>n (%)</th>
<th>Skin disease</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contact dermatitis</td>
<td>39 (9.4)</td>
<td>Psoriasis</td>
<td>9 (2.2)</td>
</tr>
<tr>
<td>Fungal infections</td>
<td>35 (8.4)</td>
<td>Recurrent aphthous stomatitis</td>
<td>8 (1.9)</td>
</tr>
<tr>
<td>Drug reactions</td>
<td>28 (6.7)</td>
<td>No dermatologic disease</td>
<td>8 (1.9)</td>
</tr>
<tr>
<td>Cellulitis</td>
<td>27 (6.4)</td>
<td>Seborrhoeic dermatitis</td>
<td>7 (1.7)</td>
</tr>
<tr>
<td>Xerosis cutis</td>
<td>15 (3.6)</td>
<td>Behçet disease</td>
<td>7 (1.7)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>15 (3.6)</td>
<td>Malignancy</td>
<td>7 (1.7)</td>
</tr>
<tr>
<td>Vasculitis</td>
<td>14 (3.4)</td>
<td>Oral candidiasis</td>
<td>7 (1.7)</td>
</tr>
<tr>
<td>Stasis dermatitis</td>
<td>14 (3.4)</td>
<td>Acniform disease</td>
<td>6 (1.4)</td>
</tr>
<tr>
<td>Herpes labialis</td>
<td>13 (3.1)</td>
<td>Rosacea</td>
<td>5 (1.2)</td>
</tr>
<tr>
<td>Infections (foliculitis, furunculosis, paronhichya)</td>
<td>13 (3.1)</td>
<td>Traumatic ulcer</td>
<td>5 (1.2)</td>
</tr>
<tr>
<td>Neurodermatitis</td>
<td>12 (2.9)</td>
<td>Spontaneous and traumatic ecchymosis</td>
<td>5 (1.2)</td>
</tr>
<tr>
<td>Urticaria</td>
<td>11 (2.6)</td>
<td>Vascular disease (thrombophlebitis, ischemia)</td>
<td>5 (1.2)</td>
</tr>
<tr>
<td>Pressure sore</td>
<td>11 (2.6)</td>
<td>Autoimmune bullous disease</td>
<td>4 (1.0)</td>
</tr>
<tr>
<td>Intertrigo</td>
<td>11 (2.6)</td>
<td>Seborrhoeic keratosis</td>
<td>4 (1.0)</td>
</tr>
<tr>
<td>Herpes zoster</td>
<td>10 (2.4)</td>
<td>Radiodermatitis</td>
<td>3 (0.7)</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>59 (14.1)</td>
<td>Total</td>
<td>417</td>
</tr>
</tbody>
</table>

patients. Skin biopsies were performed in 8.2% of cases; this was lower than the rate reported by Davila1 (20%) but higher than the rate described by Adısen (4.4%).2

In our experience, common dermatologic diseases are often not correctly diagnosed by physicians from other specialties. In addition, there is room for improvement in the formal description and in the differential diagnosis of skin diseases. Expert dermatologic assessment usually facilitates inpatient diagnosis and management. Better training should be considered for medical students and residents and possibly even for medical staff in other specialties.

References


Frontal congenital lipoma and lipoma of the corpus callosum in an infant: A case report* 

Lipoma frontal congA(c)nito y lipoma del cuerpo calloso en un lactante: Informe de un caso

To the Editor,

An otherwise healthy 4-month-old girl who had been born full-term without birth trauma or prenatal or neonatal complications was brought to our practice because of a frontal tumor that had been present since birth. Physical examination revealed a deep frontal tumor of medium consistency that was mobile, unattached to the deeper layers, and without epidermal changes (Fig. 1). The rest of the examination was normal. No hypertelorism, nasal alterations, or dysmorphic facial features were observed.

A soft-tissue cranial ultrasound performed when the infant was 2 days old showed slight thickening of the subcortaneous tissue; this was also visible in a second ultrasound performed 2 months later. The diagnosis was congenital frontal lipoma.

The patient was lost to follow-up but returned when she was 8 months old. A brain magnetic resonance imaging (MRI) study showed an interhemispheric hyperintense mass on

Markers Midline

As although Most  

Midline lipomas may be associated with central nervous system malformations, and in such cases, diverse radiologic studies and clinical follow-up are mandatory. Intracranial lipomas are also rare, accounting for just 0.06Y.0.46% of intracranial lesions. Most are located in the midline/interhemispheric region, most often in the corpus callosum. In about 50% of cases other disturbances, frequently associated with varying degrees of hypoplasia or agensis of the corpus callosum, are identified in the surrounding nervous structures. Subcutaneous lipomas in association with intracranial lipomas are even rarer. The association could be related to the abnormal migration and proliferation of neural crest cells. Abnormal neural crest development results in many craniofacial malformations, known as neurocristopathies, including facial midline clefts. Intracranial and extracranial lipomas may be independent entities or connected through a frontal bone defect on the skull.

Frontonasal dysplasia (FND) is a developmental alteration of the craniofacial region that comprises a spectrum of anomalies of the frontonasal area, including hypertelorism, nasal anomalies, and/or lip-palate cleft. The exact origin of FND is unknown and most cases are sporadic, although a mutation in the TGIF gene has been observed in familial cases of FND, which are very rare. Patients with FND may present with hypoplasia or agenesis of the corpus callosum and/or a corpus callosum lipoma. In a case series of patients with FND, all 8 patients had lipoma of the corpus callosum. Markers strongly associated with FND are falx cerebri calcifications and extracranial lipomas.

Midline lipomas of the face and other craniofacial anomalies may be associated with intracranial malformations, including intracranial lipomas. Brain MRI for the study of intracranial structures combined with clinical follow-up to monitor neurological changes seems to be the gold standard. Pai syndrome should be included in the differential diagnosis of FND-spectrum anomalies. This syndrome consists of pericallosal lipomas associated with facial abnormalities such as cutaneous polyps of the face and nasal mucosa, midline cleft, and midline pericallosal lipoma. As with our

Figure 1  A soft, mobile, asymptomatic nodule in the frontal midline area of a 4-month-old girl.

Figure 2  Interhemispheric hyperintense structure on T1-weighted image consistent with a lipoma associated with hypoplasia of the splenium of the corpus callosum (bright fat tissue on T1 sequence). (A) Sagittal plane. (B) Transverse/axial plane.
patient, a nasal fibroscopy should be performed to rule out this syndrome.

Although the majority of patients with intracranial lipomas are asymptomatic,
10,11 a small number of patients may present neurological symptoms such as seizures, headache, and/or behavioral or psychosocial disorders. Routine neurosurgical treatment is not recommended because the surgical risk usually outweighs the benefits of the intervention. Surgical resolution of extracranial lipoma may provide cosmetic improvement and better quality of life.

The prognosis and psychomotor development of patients with intracranial lipomas is not clear, but based on data from patients with FND and Pai syndrome, their prognosis would appear to be favorable, with normal psychomotor development and no neurological impairment. Some patients with FND may have psychological alterations such as mananthropy and shyness. Lipomas are rare in children and are even rarer at birth. Facial midline lipomas should be assessed by a multidisciplinary team consisting of a dermatologist, neurosurgeon, an otolaryngologist, and radiologists. Neurologic images should be taken and in cases associated with corpus callosum or pericallosal lipoma, FND and Pai syndrome must be ruled out. Whether our patient represents an isolated case of frontal congenital lipoma with associated cerebral malformation or an incomplete case within the spectrum of FND is currently unknown.

References

C. Navarrete-Dechent, a M. Curi-Tuma, b M. Sandoval-Osses a,b
a Department of Dermatology, Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile
b Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile
Corresponding author.
E-mail address: msandovallosses@yahoo.com (M. Sandoval-Osses).

Topical 0.2% Rapamycin to Treat Facial Angiofibromas and Hypomelanotic Macules in Tuberous Sclerosis

Rapamicina tópica al 0,2% para el tratamiento de angiofibromas faciales y máculas hipomelanóticas en la esclerosis tuberosa

Tuberous sclerosis is an autosomal dominant neurocutaneous disorder caused by mutations in tumor suppressor genes TSC1 (in chromosome 9q34), which encodes hamartin, and TSC2 (in chromosome 16p13.3), which encodes tuberin. Hamartin and tuberin, under normal circumstances, form a complex that inhibits the mammalian target of rapamycin (mTOR), which plays a crucial role in cell-cycle regulation. Mutations in the TSC1 and TSC2 genes lead to defective functioning of these proteins and result in uncontrolled cell proliferation that is characterized by the formation of hamartomas in multiple organs, including the skin and kidneys, and in the central nervous system. Rapamycin (sirolimus) is an immunosuppressant that inhibits the mTOR pathway. Its only approved indication is prophylaxis of renal transplant rejection. Thanks to its antineoplastic properties, sirolimus inhibits angiogenesis and tumor cell proliferation, and has also been shown to be effective in reducing the number and size of tumors in patients with tuberous sclerosis. Recent publications suggest that topical rapamycin is effective for treating facial angiofibromas and reducing hypomelanotic macules in patients with tuberous sclerosis.

We report a case of a 13-year-old boy who had been clinically diagnosed with tuberous sclerosis at age 4 months based on the presence of typical manifestations of this condition, namely epilepsy, multiple hypomelanotic macules, and facial angiofibromas. Genetic analysis confirmed sporadic tuberous sclerosis caused by a c5043C-G mutation in exon 38 of the TSC2 gene, changing the sequence

Please cite this article as: Knöpfel N, Martín-Santiago A, Bauza A, Hervás JA. Rapamicina tópica al 0,2% para el tratamiento de angiofibromas faciales y máculas hipomelanóticas en la esclerosis tuberosa. Actas Dermosifiliogr. 2014;105:802–803.